Literature DB >> 8771431

How to achieve a near 100% cure rate for H. pylori infection in peptic ulcer patients. A personal viewpoint.

W A de Boer1.   

Abstract

Infection with Helicobacter pylori is the main etiological factor in duodenal and gastric ulcer disease, and eradication of the organism cures peptic ulcer disease. Cure of the infection therefore has become the ultimate treatment goal in ulcer patients. Only therapies that achieve a > 90% cure rate should be used in clinical practice and, as in any other disease, the therapy with the highest cure rates should be used. Bismuth-based triple therapy is considered the gold standard; it has been used successfully in many studies, usually with good tolerability on the part of patients. Many physicians have been hesitant to prescribe this therapy. The regimen is complex, and it is thought to have many side effects. Several groups have shown that concomitant therapy with a proton pump inhibitor increases efficacy and lessens side effects. Moreover, it has become clear that the duration of treatment can be decreased to just 7 days. With this adjustment it now seems sensible to use this short 7-day quadruple therapy, which at present has superior cure rates when compared with any other anti-Helicobacter therapy. This article is a plea for the use of this regimen and gives practical advice about how to employ therapy in general practice. Suggestions are made about how to motivate a patient to comply with the therapy prescribed. If these suggestions are followed, good compliance seems possible, and a near 100% cure rate will be within reach.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8771431     DOI: 10.1097/00004836-199606000-00016

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  10 in total

Review 1.  Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.

Authors:  H D Langtry; M I Wilde
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

Review 2.  How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly.

Authors:  David Y Graham; Sun-Young Lee
Journal:  Gastroenterol Clin North Am       Date:  2015-06-19       Impact factor: 3.806

3.  Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis.

Authors:  Yuqin Li; Xiayue Huang; Linhua Yao; Ruihua Shi; Guoxin Zhang
Journal:  Wien Klin Wochenschr       Date:  2010-07-16       Impact factor: 1.704

Review 4.  A practical approach to patients with refractory Helicobacter pylori infection, or who are re-infected after standard therapy.

Authors:  U Peitz; A Hackelsberger; P Malfertheiner
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

Review 5.  Optimal therapy for Helicobacter pylori infections.

Authors:  Emiko Rimbara; Lori A Fischbach; David Y Graham
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-02       Impact factor: 46.802

Review 6.  Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China.

Authors:  Hong Lu; Wei Zhang; David Y Graham
Journal:  Eur J Gastroenterol Hepatol       Date:  2013-10       Impact factor: 2.566

Review 7.  Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies.

Authors:  David Y Graham; Maria Pina Dore; Hong Lu
Journal:  Expert Rev Anti Infect Ther       Date:  2018-08-23       Impact factor: 5.091

Review 8.  A rational approach to uninvestigated dyspepsia in primary care: review of the literature.

Authors:  N L A Arents; J C Thijs; J H Kleibeuker
Journal:  Postgrad Med J       Date:  2002-12       Impact factor: 2.401

Review 9.  Primer for Development of Guidelines for Helicobacter pylori Therapy Using Antimicrobial Stewardship.

Authors:  David Y Graham; Jyh-Ming Liou
Journal:  Clin Gastroenterol Hepatol       Date:  2021-03-26       Impact factor: 13.576

Review 10.  Helicobacter pylori diagnosis and therapy in the era of antimicrobial stewardship.

Authors:  Akiko Shiotani; Priya Roy; Hong Lu; David Y Graham
Journal:  Therap Adv Gastroenterol       Date:  2021-12-21       Impact factor: 4.409

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.